302 related articles for article (PubMed ID: 34247749)
21. Statins in the management of dyslipidemia associated with chronic kidney disease.
Epstein M; Vaziri ND
Nat Rev Nephrol; 2012 Feb; 8(4):214-23. PubMed ID: 22349484
[TBL] [Abstract][Full Text] [Related]
22. HMG-CoA reductase inhibitors and the kidney.
Campese VM; Hadaya B; Chiu J
Curr Hypertens Rep; 2005 Oct; 7(5):337-42. PubMed ID: 16157074
[TBL] [Abstract][Full Text] [Related]
23. [Chronic kidney disease and dyslipidaemia].
Pascual V; Serrano A; Pedro-Botet J; Ascaso J; Barrios V; Millán J; Pintó X; Cases A
Clin Investig Arterioscler; 2017; 29(1):22-35. PubMed ID: 27863896
[TBL] [Abstract][Full Text] [Related]
24. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
Heymann EP; Kassimatis TI; Goldsmith DJ
J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
[TBL] [Abstract][Full Text] [Related]
25. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
Athyros VG; Tziomalos K; Karagiannis A
Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
[TBL] [Abstract][Full Text] [Related]
26. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
Chan DT; Irish AB; Dogra GK; Watts GF
Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
[TBL] [Abstract][Full Text] [Related]
27. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
Watanabe T
Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
[TBL] [Abstract][Full Text] [Related]
28. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
29. Dyslipidemia in children with CKD: should we treat with statins?
Tullus K
Pediatr Nephrol; 2012 Mar; 27(3):357-62. PubMed ID: 21487766
[TBL] [Abstract][Full Text] [Related]
30. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
Kasiske B; Cosio FG; Beto J; Bolton K; Chavers BM; Grimm R; Levin A; Masri B; Parekh R; Wanner C; Wheeler DC; Wilson PW;
Am J Transplant; 2004; 4 Suppl 7():13-53. PubMed ID: 15027968
[TBL] [Abstract][Full Text] [Related]
31. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
32. Importance of high-density lipoprotein quality: evidence from chronic kidney disease.
Kon V; Ikizler TA; Fazio S
Curr Opin Nephrol Hypertens; 2013 May; 22(3):259-65. PubMed ID: 23470818
[TBL] [Abstract][Full Text] [Related]
33. Statin use in patients with diabetes and kidney disease: the Japanese experience.
Koya D; Campese VM
J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
[TBL] [Abstract][Full Text] [Related]
34. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].
Zavidić T; Lodeta B; Lovrinić Đ
Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular disease in patients with renal disease: the role of statins.
Fellström B; Holdaas H; Jardine AG; Svensson MK; Gottlow M; Schmieder RE; Zannad F;
Curr Med Res Opin; 2009 Jan; 25(1):271-85. PubMed ID: 19210158
[TBL] [Abstract][Full Text] [Related]
36. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
Montague T; Murphy B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
[TBL] [Abstract][Full Text] [Related]
37. Lipid management in patients with chronic kidney disease.
Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
[TBL] [Abstract][Full Text] [Related]
38. LDL-cholesterol lowering and renal outcomes.
Waters DD
Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
[TBL] [Abstract][Full Text] [Related]
39. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
[TBL] [Abstract][Full Text] [Related]
40. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
